Helus Pharma said Chief Executive Officer Michael Halstead will participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on Sept. 23, 2026. The virtual webcast is scheduled for 9:00 a.m. EDT, with a replay to be posted on the company’s investor relations website. Helus Pharma, the commercial operating name of Cybin Inc., is developing novel serotonergic agonists, or synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. Its pipeline includes HLP003 in Phase 3 development for adjunctive treatment of major depressive disorder and HLP004 in Phase 2 development for generalized anxiety disorder. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company said its product claims have not been evaluated by regulators and that rigorous research and clinical trials remain necessary.